Given that he started at Mesoblast in October, 2019 and they submitted the BLA for remestemcel-L on January 1, 2020, it seems a bit unfair to imply that he contributed to the CRL result, a very controversial result I must add. It is doubtful that he would be placed in control of the submission so early into his tenure, but of course I'm just speculating.

I would cast more blame on whoever designed the trial protocol. It appears the FDA was looking for a randomized, controlled trial.